| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Ardelyx, Inc. (ARDX) has 9 insiders with recent SEC Form 4 filings, including 10 buys and 7 sells. ARDX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 3.30M | $20.64M | - | |
| CEO | 1.74M | $10.88M | -41,666 | |
| Other | 409.9K | $2.56M | - | |
| CFO | 409.1K | $2.56M | - | |
| Other | 339.5K | $2.12M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 5, 2017 | Korner Paul | EVP, Chief Medical Officer | Sell | 6,130 | $12.95 | $79,383.50 | -10.1% | |
| Dec 16, 2016 | Rosenbaum David P.59 | SVP, Drug Development | Sell | 900 | $14.48 | $13,035.33 | -58.6% | |
| Nov 11, 2016 | Caldwell Jeremy S | EVP, Chief Scientific Officer | Sell | 2,158 | $15.13 | $32,645.58 | -100% | |
| Oct 11, 2016 | Jacobs Jeffrey W66 | SVP, Technical Operations | Sale+OE | 6,000 | $15.00 | $90,000.00 | -10.8% | |
| Sep 23, 2016 | Grammer Elizabeth A58 | SVP, General Counsel | Sale+OE | 5,000 | $12.00 | $60,000.00 | -100% | |
| Sep 19, 2016 | Grammer Elizabeth A58 | SVP, General Counsel | Sale+OE | 6,859 | $11.21 | $76,880.47 | -100% | |
| Jul 18, 2016 | Kolluri Krishna Kittu | 10% Owner | Buy | 2,290,951 | $8.73 | $20,000,002.23 | +19.4% | |
| Jul 18, 2016 | Sakoda Jon | 10% Owner | Buy | 1,527,301 | $8.73 | $13,333,337.73 | +40.2% | |
| Jul 18, 2016 | Weller Harry R | 10% Owner | Buy | 1,527,301 | $8.73 | $13,333,337.73 | +40.2% | |
| Jul 18, 2016 | Baskett Forest53 | 10% Owner | Buy | 2,290,951 | $8.73 | $20,000,002.23 | +19.4% |